Xconomy | Seattle - Business + Technology in the Exponential Economy

Biotech, Life Sciences, Stocks

Cell Therapeutics Authorizes 1-for-10 Reverse Stock Split

Luke Timmerman 8/25/08

Cell Therapeutics said today its board has authorized a 1-for-10 reverse stock split, meaning that shareholders will get one share of common stock in exchange for 10 they own. The Seattle-based biotech company (NASDAQ: CTIC) said the change will take effect Aug. 31. The move was made primarily to regain compliance with Nasdaq listing requirements, the company said. Shares of Cell Therapeutics fell 2 cents to 25 cents at 10:57 a.m. Eastern time today.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2008 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.